Quote:

---

This was an open label trial with no masking, patients were not randomly assigned, and there was no control group involved. As such, the Company inappropriately compared the results to statistics of survival for a general population of metastatic breast cancer patients. Without an actual clinical trial showing statistical significance, further progress will be difficult to obtain.

---

I have to wonder if those are the words of unknown oncologist Dr. Patterson. If so he should look at the long list of phase 2 Keytruda trials that were not blinded and had no control arm.